Eli Lilly announced clinical trial results showing its experimental weight loss medication retatrutide achieved more than twice the weight reduction of Ozempic’s maximum dose, marking a significant advancement in pharmaceutical treatments for obesity and type 2 diabetes.

Clinical Trial Results Show Major Improvements

The phase 3 clinical trial included over 1,000 adults diagnosed with type 2 diabetes. Participants receiving the 9mg dose of retatrutide lost an average of 44.3 pounds, while those on the 12mg dose lost 47.4 pounds over 80 weeks. By comparison, patients taking Ozempic’s highest 2mg dose lost only 20.9 pounds during the same period.

Beyond weight loss, retatrutide demonstrated superior cardiovascular benefits. Trial participants showed improved cholesterol levels and blood pressure readings. The medication also reduced A1C levels by 2.2 percent compared to Ozempic’s 1.8 percent reduction. A1C measurements indicate long-term blood sugar control and diabetes risk.

STAT

@statnews

Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study. trib.al/vyPRwML

Lilly’s triple-G drug beats Ozempic in head-to-head study

statnews.com

2:10 PM · Oct 28, 2026

How the Triple-Action Drug Works

Retatrutide represents a new generation of weight loss treatments by mimicking three separate hunger-regulating hormones simultaneously. The once-weekly injection targets GLP-1, GIP, and glucagon. Current market options like Ozempic and Wegovy only mimic GLP-1, which affects brain function, muscle development, and organ systems including the pancreas and liver. Mounjaro and Zepbound target both GLP-1 and GIP, which regulates blood sugar through insulin stimulation.

The third hormone retatrutide targets, glucagon, promotes fat burning even during rest periods. This triple-action approach differentiates it from all currently approved weight loss medications, potentially explaining its enhanced effectiveness in clinical trials.

Market Competition and Safety Concerns

Eli Lilly plans submitting retatrutide for Food and Drug Administration approval in early 2027. Competitor Novo Nordisk expects approval for its experimental drug CagriSema by year’s end. Neither medication currently holds FDA approval. The FDA warns consumers against purchasing versions advertised online, which come from black markets and pose serious health risks.

Currently approved treatments include Ozempic and Mounjaro for type 2 diabetes, while Wegovy and Zepbound received approval for treating overweight and obesity conditions. Healthcare providers emphasize patients should consult medical professionals before starting any prescription medication regimen. The pharmaceutical industry’s rapid development of obesity treatments reflects growing demand as Americans seek medical solutions for weight management and metabolic health conditions affecting millions nationwide.